Artiva Biotherapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Artiva Biotherapeutics, Inc. (ARTV), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are ARTV insiders buying or selling?
In the last 12 months, Artiva Biotherapeutics, Inc. insiders reported 11 open-market purchases ($109.2M) and 19 sales ($2.5M) — net buying of $106.7M. Since July 2024, Trabud has recorded 36 Form 4 filings for ARTV: 16 buys ($274.2M) and 20 sells ($2.6M).
Source: SEC EDGAR Form 4
Key Statistics (July 2024 – Oct 6, 2026)
Total Form 4 filings
36
SEC EDGAR
Insider filers
10
Insider buys (16)
$274.2M
Insider sells (20)
$2.6M
Insider sentiment
Net buyingNet insider flow of $271.6M in net buying since July 2024, and $106.7M in net buying over the last 12 months. 6 insider buys in the last 90 days.
Recent ARTV insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 6, 2026 | Christopher Horan | Chief Tech Operations Officer | Sale | 10.3K | $6.84 | $70.7K | SEC ↗ |
| Oct 6, 2026 | Jennifer Bush | COO, CLO, Compliance Officer | Sale | 8.4K | $6.84 | $57.2K | SEC ↗ |
| Oct 6, 2026 | Subhashis Banerjee | Chief Medical Officer | Sale | 1.1K | $6.84 | $7.5K | SEC ↗ |
| Oct 6, 2026 | Fred Aslan | Chief Executive Officer | Sale | 61.7K | $6.84 | $421.8K | SEC ↗ |
| Sep 9, 2026 | Fred Aslan | Chief Executive Officer | Sale | 23.4K | $10.92 | $255.7K | SEC ↗ |
| Sep 4, 2026 | Christopher Horan | Chief Tech Operations Officer | Sale | 10.4K | $11.16 | $115.6K | SEC ↗ |
| Sep 4, 2026 | Jennifer Bush | COO, CLO, Compliance Officer | Sale | 8.4K | $11.16 | $93.6K | SEC ↗ |
| Sep 4, 2026 | Subhashis Banerjee | Chief Medical Officer | Sale | 1.1K | $11.16 | $12.3K | SEC ↗ |
| Sep 4, 2026 | Fred Aslan | Chief Executive Officer | Sale | 61.9K | $11.16 | $690.4K | SEC ↗ |
| Aug 31, 2026 | Subhashis Banerjee | Chief Medical Officer | Sale | 8.2K | $12.01 | $98.7K | SEC ↗ |
| Aug 20, 2026 | Subhashis Banerjee | Chief Medical Officer | Sale | 429 | $12.00 | $5.1K | SEC ↗ |
| Jul 31, 2026 | Peter Kolchinsky | Director, 10% Owner | Purchase | 45.8K | $9.96 | $455.7K | SEC ↗ |
| Jul 28, 2026 | Peter Kolchinsky | Director, 10% Owner | Purchase | 41.3K | $9.99 | $412.8K | SEC ↗ |
| Jul 24, 2026 | Peter Kolchinsky | Director, 10% Owner | Purchase | 264.6K | $9.76 | $2.6M | SEC ↗ |
| Jul 24, 2026 | Peter Kolchinsky | Director, 10% Owner | Purchase | 6.5K | $8.94 | $58.3K | SEC ↗ |
| Jul 20, 2026 | Peter Kolchinsky | Director, 10% Owner | Purchase | 160.4K | $8.93 | $1.4M | SEC ↗ |
| Jul 14, 2026 | Peter Kolchinsky | Director, 10% Owner | Purchase | 21.7K | $8.96 | $194.0K | SEC ↗ |
| Jun 29, 2026 | Peter Kolchinsky | Director, 10% Owner | Purchase | 32.9K | $8.89 | $292.1K | SEC ↗ |
| Jun 16, 2026 | Peter Kolchinsky | Director, 10% Owner | Purchase | 531.3K | $8.66 | $4.6M | SEC ↗ |
| Jun 11, 2026 | Peter Kolchinsky | Director, 10% Owner | Purchase | 1.0M | $7.44 | $7.7M | SEC ↗ |
| May 28, 2026 | GC Corp. | 10% Owner | Purchase | 1.4M | $11.52 | $16.5M | SEC ↗ |
| May 20, 2026 | Heather Raymon | SVP, Research and Development | Sale | 3.1K | $9.01 | $27.9K | SEC ↗ |
| May 20, 2026 | Christopher Horan | Chief Tech Operations Officer | Sale | 7.0K | $9.01 | $63.1K | SEC ↗ |
| May 20, 2026 | Jennifer Bush | COO, CLO, Compliance Officer | Sale | 8.8K | $9.01 | $79.2K | SEC ↗ |
| May 20, 2026 | Subhashis Banerjee | Chief Medical Officer | Sale | 7.0K | $9.01 | $63.4K | SEC ↗ |
Showing the 25 most recent of 36 Form 4 filings for Artiva Biotherapeutics, Inc..
Most active ARTV insiders
- Peter Kolchinsky11 filings
- Fred Aslan8 filings
- Subhashis Banerjee5 filings
- Christopher Horan3 filings
- Jennifer Bush3 filings
Ask anything about ARTV insider activity
Use Trabud's AI agent to query Artiva Biotherapeutics, Inc.'s Form 4 history in plain English — "Show me ARTV CEO purchases this year" or compare it against any other ticker.
Open the AI agentARTV insider trading FAQ
Are Artiva Biotherapeutics, Inc. insiders buying or selling?
In the last 12 months, Artiva Biotherapeutics, Inc. insiders reported 11 open-market purchases ($109.2M) and 19 sales ($2.5M) — net buying of $106.7M. Since July 2024, Trabud has recorded 36 Form 4 filings for ARTV: 16 buys ($274.2M) and 20 sells ($2.6M). Over the full record that is net buying of $271.6M.
How many insiders trade ARTV stock?
10 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Artiva Biotherapeutics, Inc.. The most recent filing was accepted on Oct 6, 2026.
Where does Trabud get ARTV insider trading data?
All ARTV insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.